Autopsy report · NCT05676853

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 1 month before it stopped.
3 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Aeglea Biotherapeutics
Sponsor type: Industry
Conditions: Arginase I Deficiency; Hyperargininemia
Interventions: Pegzilarginase
Participants: 3
Sites: 1
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.